1. Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials. Issue 2 (February 2015) Authors: Yang, James Chih-Hsin; Wu, Yi-Long; Schuler, Martin; Sebastian, Martin; Popat, Sanjay; Yamamoto, Nobuyuki; Zhou, Caicun; Hu, Cheng-Ping; O'Byrne, Kenneth; Feng, Jifeng; Lu, Shun; Huang, Yunchao; Geater, Sarayut L; Lee, Kye Young; Tsai, Chun-Ming; Gorbunova, Vera; Hirsh, Vera; Bennouna, Jaafar; Or... Journal: Lancet oncology Issue: Volume 16:Issue 2(2015:Feb.) Page Start: 141 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials. Issue 2 (February 2015) Authors: Yang, James Chih-Hsin; Wu, Yi-Long; Schuler, Martin; Sebastian, Martin; Popat, Sanjay; Yamamoto, Nobuyuki; Zhou, Caicun; Hu, Cheng-Ping; O'Byrne, Kenneth; Feng, Jifeng; Lu, Shun; Huang, Yunchao; Geater, Sarayut L; Lee, Kye Young; Tsai, Chun-Ming; Gorbunova, Vera; Hirsh, Vera; Bennouna, Jaafar; Or... Journal: Lancet oncology Issue: Volume 16:Issue 2(2015:Feb.) Page Start: 141 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial. Issue 5 (May 2016) Authors: Park, Keunchil; Tan, Eng-Huat; O'Byrne, Ken; Zhang, Li; Boyer, Michael; Mok, Tony; Hirsh, Vera; Yang, James Chih-Hsin; Lee, Ki Hyeong; Lu, Shun; Shi, Yuankai; Kim, Sang-We; Laskin, Janessa; Kim, Dong-Wan; Arvis, Catherine Dubos; Kölbeck, Karl; Laurie, Scott A; Tsai, Chun-Ming; Shahidi, Mehdi; Kim... Journal: Lancet oncology Issue: Volume 17:Issue 5(2016:May) Page Start: 577 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. Clinical activity of afatinib in patients with advanced non-small-cell lung cancer harbouring uncommon EGFR mutations: a combined post-hoc analysis of LUX-Lung 2, LUX-Lung 3, and LUX-Lung 6. Issue 7 (July 2015) Authors: Yang, James C-H; Sequist, Lecia V; Geater, Sarayut Lucien; Tsai, Chun-Ming; Mok, Tony Shu Kam; Schuler, Martin; Yamamoto, Nobuyuki; Yu, Chong-Jen; Ou, Sai-Hong I; Zhou, Caicun; Massey, Daniel; Zazulina, Victoria; Wu, Yi-Long Journal: Lancet oncology Issue: Volume 16:Issue 7(2015:Jul.) Page Start: 830 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. First‐Line Afatinib versus Chemotherapy in Patients with Non–Small Cell Lung Cancer and Common Epidermal Growth Factor Receptor Gene Mutations and Brain Metastases. Issue 3 (March 2016) Authors: Schuler, Martin; Wu, Yi‐Long; Hirsh, Vera; O'Byrne, Kenneth; Yamamoto, Nobuyuki; Mok, Tony; Popat, Sanjay; Sequist, Lecia V.; Massey, Dan; Zazulina, Victoria; Yang, James C.‐H. Journal: Journal of thoracic oncology Issue: Volume 11:Issue 3(2016) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. Original Article: Non–Small Cell Lung Cancer - First-Line Afatinib versus Chemotherapy in Patients with Non–Small Cell Lung Cancer and Common Epidermal Growth Factor Receptor Gene Mutations and Brain Metastases. Issue 3 (March 2016) Authors: Schuler, Martin; Wu, Yi‐Long; Hirsh, Vera; O'Byrne, Kenneth; Yamamoto, Nobuyuki; Mok, Tony; Popat, Sanjay; Sequist, Lecia V.; Massey, Dan; Zazulina, Victoria; Yang, James C.‐H. Journal: Journal of thoracic oncology Issue: Volume 11:Issue 3(2016) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗